Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Fine, Kaplan and Black, R.P.C. 律師事務所宣佈集體訴訟和解案,若您於 2009 年 5 月 1 日至 2019 年 12 月 31 日期間,在美國境內曾支付或報銷特定處方通用藥品費用,請注意以下事項
  • USA - English
  • USA - Chinese
  • USA - español


News provided by

Fine, Kaplan, and Black, R.P.C.

Oct 03, 2025, 18:00 ET

Share this article

Share toX

Share this article

Share toX

費城 2025年10月3日 /美通社/ -- 

法律聲明

在 2009 年 5 月 1 日至 2019 年 12 月 31 日期間,如果您支付或報銷了特定處方學名藥的費用,您可以從集體訴訟和解決方案中獲得付款。

本公告經聯邦法院授權。
這並非律師的邀請。

1-877-316-0171
www.GenericDrugsEndPayerSettlement.com 

您在集體訴訟案(參見《處方學名藥反壟斷訴訟案》(In re Generic Pharmaceuticals Antitrust Litigation),案件編號:16-MD-2724 (E.D.Pa.))中與 Sun Pharmaceutical Industries, Inc.(簡稱「Sun」)及 Taro Pharmaceuticals U.S.A.(簡稱「Taro」)達成的 2 億美元和解協議(以「Sun/Taro」指代兩間公司),可能影響您的法定權利。該訴訟指控學名藥製造商違反聯邦及州反壟斷法、消費者保護法規與普通法,導致最終付款方——包括消費者與第三方付款方(簡稱「TPP」)(例如保險公司或設有自籌資金處方藥計劃的雇主等實體)——為特定學名藥(即「指定學名藥」)支付了超出應有金額的費用。Sun/Taro 聲明不承擔責任。針對未和解被告的訴訟仍在進行中。

我是否屬於和解集體成員?該訴訟由指定類藥物的最終付款人(簡稱「EPP」)提出,法院已預先認證由 TPP 和消費者組成的 EPP Sun/Taro 結算類別。如果您符合以下條件,即可能屬於 EPP Sun/Taro 和解集體成員:身為 TPP 或消費者,曾間接購買、支付及/或為下列情況之一或多項支付部分或全部購藥費用,供您本人或成員個人使用且非以轉售為目的,於 2009 年 5 月 1 日至 2019 年 12 月 31 日期間任何時間,在美國境內(印第安納州與俄亥俄州除外)及部分美國屬地,進行上述行為。某些類型的實體,不包括在 EPP Sun/Taro 結算類別。一份更詳盡的通知已發佈,當中包括完整的訴訟類別說明及適用對象範圍;指定學名藥清單;被告完整名單;以及和解協議書,可於以下連結查閱: www.GenericDrugsEndPayerSettlement.com (「EPP Settlement Website」)。

和解協議提供了哪些內容?根據擬議的和解協議,Sun/Taro已向和解基金支付2億美元。根據《和解協議》所述,結算基金可能會在某些情況下減少。根據擬議和解方案,Sun/Taro 已向和解基金支付 2 億美元。該筆款項將用於支付符合資格的 EPP Sun/Taro 和解集體成員,扣除和解通知及行政費用(上限 75 萬美元)後; 並在法院核准前提下,支付律師費(上限為基金總額三分之一加計利息)、未償還訴訟支出,以及針對剩餘被告後續訴訟之未來支出額外款項(過往及未來支出合計上限 400 萬美元),另包含和解群體代表之服務獎勵(總額上限 50 萬美元)。和解集體訴訟律師將把其關於律師費、訴訟支出及服務獎勵的請求張貼於 EPP 和解網站上。Sun/Taro 亦同意與環保人士合作,提供 EPP 對非調解被告訴訟有關的資料。

如何獲得付款?如果法院批准和解後,將分配資金。付款金額和時間,將根據必須經法院批准的配置計劃行事。EPP 提出的分配方案已發佈於 EPP 和解網站。索償程序將在稍後開始。若要收到與定居相關的最新資訊,包括提供索償表格時,您應在 EPP 結算網站註冊,或致電以下免費電話號碼。

若我身為 EPP Sun/Taro 和解集體訴訟成員,有哪些選擇? 如果您不採取任何行動,您將仍然是 EPP Sun/Taro 結算類別成員,符合參與和解的資格,並受法院關於和解的裁決和對 Sun/Taro 的訴訟的法律約束,並且您將無法向 Sun/Taro 提起訴訟。如果您不希望受《和解》的法律約束,或者如果您想保留自己的訴訟 Sun/Taro 的權利,則必須排除自己。若您選擇保留集體成員資格,但對和解協議部分或全部內容、擬議分配方案、律師費用及支出請求或擬議服務獎勵提出異議,您可提出反對。有關如何申請排除或反對的詳細資訊,請參閱 EPP 結算網站。任何排除要求或異議,必須在 2025 年 12 月 2 日之前提交。法院將於 2026 年 1 月 15 日上午 11 時舉行公平聆訊以決定是否批准和解協議、分配計劃及任何關於律師費、開支或服務獎勵的請求。若您希望出席聽證會,必須向法院提交「出庭意向通知書」,並可自行聘請律師代為出庭(但非強制要求),相關費用需自行負擔。法院可更改截止日期或聽證會日期與時間。請查看 EPP 結算網站以獲取更新。

關於《處方學名藥最終付款人反壟斷訴訟案》(In re Generic Pharmaceuticals End-Payer Antitrust Litigation)
收件人:A.B. Data, Ltd.
P.O. Box 173118
Milwaukee, WI 53217

如需更多資訊:請致電 1-877-316-0171 或瀏覽 www.GenericDrugsEndPayerSettlement.com。

Fine, Kaplan, and Black, R.P.C.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

Fine, Kaplan and Black, R.P.C., Announce a Class Action Settlement If You Paid or Reimbursed for Certain Prescription Generic Drugs in the United States Between May 1, 2009 and December 31, 2019

LEGAL NOTICE If You Paid or Reimbursed for Certain PRESCRIPTION GENERIC DRUGS in the United States between May 1, 2009 and December 31, 2019, You...

Fine, Kaplan and Black宣布达成集体诉讼和解

法律声明 若您曾于2009年5月1日至2019年12月31日期间在美国境内支付或报销过特定处方仿制药费用,您可能有资格获得集体诉讼和解赔偿金。 本声明经联邦法院授权发布。 本函并非律师发布的委托邀请。 1-877-316-0171...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Banking & Financial Services

Banking & Financial Services

Pharmaceuticals

Pharmaceuticals

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.